MARKET

BIVI

BIVI

Biovie Inc
NASDAQ
1.330
-0.050
-3.62%
Opening 11:31 05/15 EDT
OPEN
1.350
PREV CLOSE
1.380
HIGH
1.372
LOW
1.320
VOLUME
22.35K
TURNOVER
--
52 WEEK HIGH
12.10
52 WEEK LOW
1.060
MARKET CAP
10.03M
P/E (TTM)
-0.2590
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 3d ago
BioVie Q3 FY26 net loss widens to $5.3 million; operating expenses climb to $5.4 million
PUBT · 3d ago
Weekly Report: what happened at BIVI last week (0504-0508)?
Weekly Report · 4d ago
Weekly Report: what happened at BIVI last week (0427-0501)?
Weekly Report · 05/04 09:32
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 05/01 21:05
BioVie To Host Virtual Key Opinion Leader Event On May 7 To Discuss Phase 2 Trial Of Bezisterim To Treat Parkinson's Disease
Benzinga · 04/27 12:03
Weekly Report: what happened at BIVI last week (0420-0424)?
Weekly Report · 04/27 09:33
Why United Rentals Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Benzinga · 04/23 09:18
More
About BIVI
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.

Webull offers BioVie Inc stock information, including NASDAQ: BIVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIVI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIVI stock methods without spending real money on the virtual paper trading platform.